Sun Pharma surges 4%, hits 52-week high; stock rallies 76% from March-low
For the quarter ended June 2020, Sun Pharma reported a surprise loss due to one-time charges.28-08-2020
28-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Chairman Speech At The 28Th Annual General Meeting
Chairman Speech at the 28th Annual General Meeting of Sun Pharmaceutical Industries Ltd., held on August 27, 202027-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 28th Annual General Meeting of Sun Pharmaceutical Industries Limited ('Company') held on August 27, 2020 pursuant to Clause 13 of Para A of Part A of Schedule III of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').27-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 26, 2020 for Raksha Sudhir Valia26-08-2020
Sun Pharma arm resolves product promotion investigation with US justice dept
"DUSA fully cooperated with DOJ in its investigation of a complaint filed by a former employee in September 2016, Sun Pharmaceutical Industries said in a regulatory filing.25-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release of our subsidiary company relating to civil settlement agreements with US Department of Justice. Please find enclosed herewith a Press Release issued by our subsidiary company in U.S.A., Sun Pharmaceutical Industries Inc., relating to resolution of US Department of Justice (DOJ) investigation by its subsidiary company, Dusa Pharmaceuticals Inc. (Dusa). Sun Pharmaceutical Industries Ltd. had already disclosed about an in-principle agreement (in respect of which now Dusa has interalia signed the civil settlement agreements with the DOJ) in the notes to consolidated accounts of its March-2020 quarterly financial results and had made a provision of Rs. 156.36 Crores for this settlement. This is for your information and dissemination.25-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for loss of Share Certificate.18-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details of issue of duplicate share certificates.14-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 13, 2020 for Aditya Medisales Ltd13-08-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 13, 2020 for Shanghvi Finance Pvt Ltd13-08-2020